Abstract Several novel drug classes have been developed for multiple myeloma treatment within the last decade. The immunomodulatory drugs, thalidomide and lenalidomide, and the first-in-class proteasome inhibitor, bortezomib, target not only the malignant plasma cells but also key stromal cell support for the neoplastic clone. All three compounds have proven efficacy in advanced disease and increasing evidence for excellent response rates and clinical benefit in newly diagnosed patients. Attention is now focused on producing rational molecularly based drug combinations, incorporating both novel agents and conventional drugs, to further improve outcome. In the setting of autologous stem cell transplantation, the incorporation of these therapies into transplant-based treatment has recently been shown to result in superior overall survival, as have other combinations in relapsed disease, such as bortezomib with liposomally encapsulated doxorubicin. Several new agents are now in clinical trials or are at advanced stages of pre-clinical studies. These include second generation proteasome inhibitors, as well as inhibitors of heat shock proteins, histone deacetylases, receptor tyrosine kinases, and agents targeting the microenvironment of tumors, including defibrotide.
Introduction
Recent research into the pathophysiology of multiple myeloma (MM) has increased our understanding of the disease and, consequently, the knowledge base from which to develop novel targeted therapies. A greater insight into two broad areas in particular-the role of the tumor microenvironment and tumor genetics-has been crucial both in highlighting hitherto unknown disease heterogeneity and in providing a new paradigm through which to assess promising new agents. The two major therapeutic classes that have been FDA-approved for MM treatment in the last decade, immunomodulatory drugs and proteasome inhibitors, represent clinical advances derived at least in part because of their ability to target both the neoplastic clone and the local tumor microenvironment. It is also likely that further therapeutic advances will require the targeting of aberrant signaling pathways specific to tightly defined molecular genetic subtypes of MM.
Tumor microenvironment in MM
The complex interactions between malignant plasma cells and the surrounding tumor microenvironment are now recognized as central to disease biology and drug resistance [1] . MM cells interact with diverse partners including bone marrow (BM) stromal cells, osteoblasts, osteoclasts and extracellular matrix proteins, which trigger in MM cells the activation of pathways that support cell proliferation and survival, as well as confer resistance of MM cells to conventional therapies (as reviewed in [1] [2] [3] ). There exist in parallel autocrine and paracrine loops through which multiple cytokines including interleukin-6 (IL-6), insulinlike growth factor-1 (IGF-1), tumor necrosis factor alpha (TNF-α), interleukin-1 beta (IL-1β), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) support tumor proliferation, resistance to various pro-apoptotic stimuli including conventional chemotherapeutic drug classes such as corticosteroids or alkylating agents. These cytokines also enhance the recruitment of new blood vessels and/or the increased bone resorption observed in MM (as reviewed in [1] [2] [3] ).
Thalidomide
Thalidomide (Thal) is a glutamic acid derivative which was first synthesized in 1953 [4] and was initially widely prescribed both as a sedative and for morning sickness. However, its teratogenicity soon became apparent, and Thal was taken off the market. In subsequent decades, evidence of beneficial activity in immune-mediated conditions such as erythema nodosum and Behcet's disease prompted both the re-positioning of Thal as an immunomodulatory agent and a re-evaluation of its therapeutic potential. As prominent bone marrow vascularization was known to correlate with disease activity and prognosis in MM [5] , the antiangiogenic activity of Thal provided the rationale for the initial clinical assessment where promising activity was shown in patients with advanced disease [6] .
Extensive in vitro work to delineate the mechanism of action of Thal in MM has revealed diverse effects, both in malignant plasma cells and in the bone marrow microenvironment. Thal directly inhibits MM cell growth during the G1 phase and induces apoptosis via caspase 8 [7] . Thal also suppresses TNF-α activity both by increasing the degradation of TNF-α mRNA and by stimulating the inhibitory effects of α1-glycoproteins on TNF-α [8] . In addition, disruption of the adhesion between MM cells and BM stromal cells abrogates cell-adhesion-mediated drug resistance mechanisms. Finally, there are several immunomodulatory effects that may have clinical relevance: activation of CD3+ T-cells, stimulation of NK-cell-mediated cytotoxicity and an increase in the levels of Interleukin-2 (IL-2) and interferon-γ (IFN-γ) [9] .
The pivotal phase II study of Thal was conducted in 84 patients with relapsed previously treated MM [6] . Despite previous high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) in most of these patients, the overall response rate (ORR) was 32%, including complete response (CR) or near CR (nCR) in 10% of patients. In the absence of any randomized controlled trials of Thal monotherapy in relapsed or refractory MM, a systematic review of 42 communications encompassing results from 1,674 patients found an ORR of 29.4% and a median overall survival (OS) of 14 months [10] .
Pre-clinical evidence of enhanced anti-MM activity of Thal combination with dexamethasone (Dex) [11] prompted several phase II trials in advanced disease. An ORR of approximately 50% was seen in these studies [12] [13] [14] . Thal-Dex is also a valid option in the setting of relapse after HDT and ASCT [15] . Follow-up data on the benefit conferred by the addition of a third or more agents is now available from several centers. Cyclophosphamide For older patients not eligible for HDT and ASCT, melphalan and prednisolone (MP) had been the standard of care until recently. Two large randomized studies have now reported on the superiority of MP-Thal (MPT) over MP. In the GIMEMA trial, patients with newly diagnosed MM aged 60 to 85 years were assigned to receive MP for six 4-week cycles plus Thal 100 mg daily continuously until any sign of relapse or progressive disease, or MP alone. The ORRs were 76% for MPT and 47.6% for MP and the 3-year OS rates were 80% for MPT and 64% for MP [26] . In the French IFM99-06 study, the addition of Thal increased the median OS by almost 2 years [27].
The Arkansas group have completed a large phase III trial to determine whether the addition of Thal would prolong survival in 668 patients following a tandem transplant-based protocol. At a median follow-up of 42 months, both the CR rate (62% versus 43%) and the 5-year event-free survival (EFS) rate (56% versus 44%) were significantly better in those receiving Thal [28] . Interpretation of the lack of benefit in OS is complicated by the finding that 83% of patients in the control arm received Thal after relapse, perhaps thereby suggesting that the withholding of Thal until relapse is a valid alternative strategy.
The principle side effects associated with the use of Thal include sedation, constipation, peripheral neuropathy and deep venous thrombosis (DVT). Patients generally adjust to the sedation, which can be minimized by taking the tablet at night. Equally, the constipation can be managed by coprescribing laxatives. The neuropathy, however, can be more problematic. In a study of 75 patients with relapsed/ refractory MM receiving Thal at a median dose-intensity of 373 mg per day, the actuarial incidence of neuropathy increased from 38% at 6 months to 73% at 12 months [29] . Doses between 100 and 200 mg daily are currently thought to represent the optimal balance between clinical efficacy and toxicity, but individualized dosing to each patient's tolerance is necessary [30] . The risk of Thal-emergent DVT in MM is increased by chemotherapy and/or steroids. Lack of certainty regarding the extent of increased risk of DVT, however, has complicated decisions regarding the use of these protocols. A recent meta-analysis of 50 articles detailing over 3,300 patients on Thal-based protocols indicated that Thal, Dex or their combination increased the risk of DVT in MM by 2.6, 2.8 and 8 times respectively [31] . Importantly, the authors also noted that prophylactic doses of low-molecular-weight heparin or warfarin at a therapeutic International Normalized Ratio substantially reduces the risk, as does aspirin, although the latter remains controversial in terms of dose and degree of protection conferred.
Lenalidomide
Research focused on increasing the therapeutic potency and reducing the problematic toxicity of Thal led to the rapid development of the structural analogue lenalidomide (Len) [32] . The clinical efficacy results from a combination of direct induction of apoptosis, inhibition of TNF-α, downregulation of NF-κB and IL-6, inhibition of angiogenesis, and the activation of several components of the immune system including T-cells, NK cells, and enhanced antibodydependent cell-mediated cytotoxicity [7, 9, 11] .
The original phase I trial of lenalidomide (CC-5013) in relapsed and refractory relapsed MM showed manageable adverse events: no dose-limiting toxicity (DLT) were observed in patients treated at any dose level within the first 28 days, while grade 3 myelosuppression developed after day 28 in all 13 patients treated with 50 mg/d Len. However, dose reduction to 25 mg/d was well tolerated and therefore considered the maximal tolerated dose (MTD). Importantly, no significant somnolence, constipation, or neuropathy has been seen in any cohort. Best responses of at least 25% reduction in paraprotein levels occurred in 17 of 24 (71%) patients, including 11 (46%) patients who had received prior Thal. Stable disease (less than 25% reduction in paraprotein) was observed in an additional 2 (8%) patients. Therefore, 17 (71%) of 24 patients (90% CI, 52-85%) demonstrated benefit from treatment.
Based on this encouraging experience, a large phase II trial examined the safety and efficacy of 2 doses of Len in advanced MM. The CR or PR rate was 17% and an additional 9% of patients achieved a minor response (MR) [33] . A total of 68 patients with progressive or stable disease after two 28-day cycles then received Len and Dex (Len-Dex). A third of these patients responded. The rates of both DVT and peripheral neuropathy were only 3%. Interestingly, all cases of DVTs were observed in the context of the Len-Dex combination regimen. Based on these and other results, the consensus dose for further study was 25 mg per day given for 21 days of a 28 day cycle.
A North American MM-009 (n=354) and a European/ Australian MM-010 (n=351) randomized trial assessed LenDex versus Dex only in patients with relapsed/refractory MM. Both trials were closed to further recruitment when interim analyses revealed that the ORRs with Len-Dex (MM-009: 61.2%; MM-010 58%) were greater than twice the response rates seen with single-agent Dex (MM-009: 22.8%; MM-010 21.7%) [34] . The rates of DVT were substantially higher among those receiving Len-Dex (MM-009 15% versus 3.5%; MM-010 8.5% versus 4.5%). The lower DVT rate in the European/Australian trial was thought by some experts to reflect lower use of erythropoiesisstimulating agents in these centers and provided further support for recent data on the prothrombotic potential of this class [35] . Although grade 3-4 neutropenia occurred more commonly in patients treated with Len-Dex (24 and 16.5% versus 3.5 and 1.2%), grade 3-4 neuropathy was seen in less than 5% of those receiving Len. As clinicians have faced the challenge of rationally integrating newly approved therapies in MM, data on which to base decisions regarding the appropriate sequencing of agents remains scarce. In this regard, a study into the extent to which prior treatment with Thal affects the efficacy of Len-Dex found that the ORRs (53% versus 63%) and CR rates (8% versus 18%) were lower in those who had previously received Thal [36] .
Len-Dex can also serve as a "backbone" for more complex multi-agent regimens. Among 17 evaluable patients with late-stage MM who received the combination of Len, cyclophosphamide and Dex, 65% achieved PR and 6% CR [37] . Over two-thirds of patients, however, required G-CSF support, and 22% of patients developed neutropenic fevers despite antibacterial prophylaxis. Early results from a German multi-center phase I/II trial of doxorubicin, Len and Dex in 31 previously treated patients with MM have been reported. The partial response (PR) rate was 84%, with a CR rate of 3% [38] . The addition of Len to the DVd (pegylated liposomal doxorubicin, vincristine, Dex) regimen resulted in an ORR of 75%, with 29% of patients achieving a CR or nCR [39] . DVTs occurred in 9% of patients despite daily prophylaxis with aspirin (dosed at 81 mg/day).
Len-Dex was then assessed as induction therapy in patients with newly diagnosed disease. An ORR of 91% was seen including 6% achieving CR and 32% meeting criteria for both very good PR (VGPR) and nCR [40] . Given these excellent results, the ECOG E4A03 trial randomized patients between Len-Dex and Len-low-dose Dex (40 mg Dex once weekly) in order to determine if a reduced dose of corticosteroid would decrease toxicity without compromising response. Remarkably, a statistically significant increase in rate of DVTs/PEs and infections (as well as a trend for significant increase in hyperglycemia and cardiac ischemia) among those receiving high-dose Dex, compared to the low-dose Dex arm, contributed to an OS difference of 10% favoring the low-dose cohort, prompting the cessation of the trial in May 2007.
As with Thal, the results from trials that added Len to the standard MP regimen were awaited with interest. A total of 54 patients over 65 years of age received 9 cycles of Len-MP followed by maintenance with intermittent Len alone in a phase II trial. The ORR was 86% and 24% achieved an immunofixation-negative CR [41] . The progression-free survival (PFS) was 87% at 16 months after a median follow-up of just under 10 months. This study provided the basis for the ongoing European Myeloma Network phase III study comparing MP with Len-MP with or without Len maintenance.
Len has a toxicity profile distinct from that of Thal. Rather than sedation, constipation or peripheral neuropathy, the primary adverse effect is myelosuppression. In the phase II trial, grade 4 neutropenia and thrombocytopenia occurred in 12 and 16% of patients, respectively, and responded to dose reduction and granulocyte colonystimulating factor (GCSF) support [33] . The incidence of DVT is low with Len alone. It occurs in up to 10% of patients with Len plus low-dose Dex, and increases further to approximately 20% for Len and high-dose Dex, despite the use of aspirin at 325 mgs/day. It is likely therefore that either warfarin or low molecular weight heparin will continue to be required as prophylaxis in high-risk patients until results of trials comparing aspirin with warfarin and other anti-thrombotic agents in patients receiving Len-Dex (at low dose) for newly diagnosed MM become available.
Bortezomib
Proteasome inhibition represents a new approach to the treatment of hematologic malignancies [42] . The proteasome consists of a multicellular complex with chymotryptic, tryptic and post-glutamyl peptide hydrolytic-like activities. Bortezomib (Velcade®) is a boronic acid dipeptide that reversibly inhibits the chymotryptic-like activity by binding to the beta-5 subunit of the complex, thereby preventing the orderly turnover of multiple regulatory proteins. The consequent cellular stress response, disruption of adhesion to the microenvironment, and inhibition of cytokine circuits leads to the activation of caspase-dependent apoptotic pathways. The effects of bortezomib are also partly mediated through inhibition of the nuclear factor NF-ĸB signaling pathway. Preclinical studies also supported a role for bortezomib in potentiating MM cells to akylating agents and corticosteroids [43] .
Following encouraging results from a phase I trial in patients with diverse hematologic malignancies [44] , the SUMMIT phase II study enrolled 202 patients with relapsed/refractory MM who received four doses of bortezomib 1.3 mg/m 2 on a 3-week cycle for up to 8 cycles. Dex was added for suboptimal response. The ORR was 35% with a CR and nCR rate of 10% [45] . CREST was an open-label, randomized trial investigating the efficacy of to doses of bortezomib, 1.0 or 1.3 mg/m 2 , on the same schedule as SUMMIT [46] . The ORR for single-agent bortezomib was 30% and 38% in the 1.0 mg/m 2 (8 of 27 patients) and 1.3 mg/m 2 (10 of 26 patients) groups respectively, suggesting that dose reduction due to toxicity should not preclude a clinically beneficial effect.
In the APEX phase III study, 669 patients with advanced MM were randomized to bortezomib or high-dose Dex. The combined CR and PR rates were 38% for bortezomib and 18% for Dex, and the CR rates were 6% and less than 1%, respectively [47] . In a study analyzing the impact of del(13) status on response and survival following treatment with either bortezomib or high-dose Dex in patients in the SUMMIT and APEX trials, bortezomib appeared to overcome some of the poor impact of del (13) as an independent prognostic factor [48] .
Several groups have investigated the efficacy of bortezomib in association with both conventional and newer agents. The combination of bortezomib, low-dose cyclophosphamide and high-dose Dex resulted in a response rate of 82% in 50 evaluable patients and a median EFS of 12 months [49] . Thirty-four patients were accrued into a phase I/II dose escalation study of Bortezomib and melphalan. The PR and CR/nCR rates were 32% and 15%, respectively, and toxicity was acceptable [50] . The MTD was bortezomib 1.0 mg/m 2 and melphalan 0.1 mg/kg. A phase I study of bortezomib and pegylated liposomal doxorubicin in relapsed and refractory MM reported an ORR of 73%. Mature follow-up on this cohort confirms the response to be sustained over time to retreatment prolonged from a median of 5.9 months after the patient's prior therapy to 24.2 months after the combination [51] .
The U.S. Food and Drug Administration (FDA) recently approved the use of liposomal doxorubicin in combination with bortezomib to treat MM patients who have not previously received bortezomib and have received at least one prior therapy. This approval was based on the results of a pre-planned, interim analysis from an international, multicenter, phase III, randomized, open-label study of 646 patients with relapsed or refractory multiple myeloma who had not previously received bortezomib. That study compared the combination of bortezomib with liposomal doxorubicin to bortezomib alone and showed that median TTP of 9.3 months for the combination versus 6.5 months for bortezomib alone [p<0.0001; HR 0.55; 95% CI (0.43, 0.71)] [52] .
When administered to those with newly diagnosed MM, bortezomib and Dex resulted in response rates of 66-88% [53, 54] . A preliminary analysis of the IFM phase III study comparing Vel and Dex with VAD prior to HDT and ASCT found that 78% of those receiving bortezomib and Dex achieved VGPR or better as opposed to 55% of those on VAD. As a result, fewer of this cohort needed to proceed to a second transplant [55] . In a study of bortezomib, doxorubicin and Dex (PAD) as induction therapy, 20 of 21 patients (95%) achieved at least a PR including CR in five patients (24%) [56] . A HOVON phase III study is currently comparing PAD and VAD as initial treatment prior to HDT-ASCT. The recently updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Multiple Myeloma endorse both regimens as first-line therapeutic options for patients proceeding to transplant.
The addition of bortezomib to standard MP (VMP) has been evaluated in 60 elder patients in a phase I/II trial. When the responses were compared with those of historical controls who received MP alone, the ORRs (89 versus 42%) and OS rates (90 versus 62%) were significantly superior in those who received VMP [57] . The large international VISTA phase III trial comparing VMP to MP in newly diagnosed patients has recently completed accrual and the results are eagerly awaited.
The addition of bortezomib to the Thal-Dex (VTD) regimen was an integral part of the tandem transplant-based protocol, Total Therapy 3. Induction chemotherapy prior to and consolidation chemotherapy after transplants each consisted of two cycles of VTD-PACE and 3-year maintenance comprised monthly cycles of VTD in the first and TD in the remaining years. Early results on 303 newly diagnosed patients reveal that at a median follow-up of 20 months, 2-year estimates of EFS, and OS were 84 and 86% respectively [58] .
The most common side effects reported with bortezomib are fatigue and gastrointestinal upset, including nausea and diarrhea. In the more formal reporting of clinical trial results, the most frequent drug-related grade 3 and 4 events were peripheral neuropathy and thrombocytopenia. Sensory neuropathy was reported by 27% of patients enrolled in the APEX study. Encouragingly, two thirds of these patients went on to experience either lessening in the severity of their symptoms or complete resolution [47] . The cyclical thrombocytopenia is due to reversible arrest in megakaryocyte maturation, does not appear to be cumulative and the 3-week protocol allows for complete recovery between cycles. Interestingly, low rates of DVT have been seen in bortezomib-treated patients and a protective effect related to bortezomib-induced thrombocytopenia and thrombomodulin release has been suggested [59] .
Combinations of novel agents
Laboratory evidence supporting potential synergy between Len and bortezomib [7] led to a phase I trial in heavily pretreated MM patients [60] , which established that Len 15 mg and bortezomib 1.0 mg/m 2 offered optimal balance between efficacy and toxicity. Out of 36 evaluable patients, the ORR was 58% after a median of 6 cycles with a favorable profile of side effects and durable responses. A phase II "Rev-Vel" study is currently accruing patients and studies of the "RevVel-Dex" combination in newly diagnosed patients and in relapsed/refractory disease are also showing great promise [61] .
The combination of bortezomib, Thal and Dex (VTD) has also been assessed. A total of 38 patients with newly diagnosed MM received up to three courses of standard dose bortezomib, three 4-day blocks of Dex 20 mg/m 2 each cycle, and Thal 100 mg per day increasing to a maximum of 200 mg per day. The ORR was 87% with a 16% CR rate [62] . A phase III trial in Italy is currently comparing VTD with Thal-Dex as induction therapy and consolidation therapy prior to and after double autologous transplantation for younger patients with newly diagnosed MM.
In a clinical trial of bortezomib, pegylated liposomal doxorubicin and Thal (VDT), the response rate among 18 heavily pre-treated patients was 56%, and included a CR rate of 22%. No significant grade 3/4 non-hematological toxicities were noted [63] .
Thirty patients with relapsed/refractory MM received the four-drug regimen bortezomib, melphalan, prednisone, and Thal (VMPT), and a PR was seen in 67% [18] . Among 14 patients who received VMPT as second-line treatment, the PR rate was 79% and the immunofixation-negative CR rate 36%. Contrary to prior concerns, the incidence of neurotoxicities was low.
Investigational agents
Several novel drug classes are currently in advanced stages of pre-clinical development or early phase I/II trials [64] .
Extensive clinical experience has been generated on new proteasome inhibitors, heat shock protein 90 (Hsp90) inhibitors, 2-methoxyestradiol, histone deacetylase (HDAC) inhibitors, arsenic trioxide, perifosine and vascular endothelial growth factor receptor (VEGF-R) inhibitors. Other compounds listed below-fibroblast growth factor receptor 3 inhibitors, atiprimod, IGF-1 receptor inhibitors, mammalian target of rapamycin (mTOR) inhibitors and IκB kinase (IKK) inhibitors-have generated promising results in preclinical studies in vitro and/or in vivo, representing interesting candidates for phase I studies.
Proteasome inhibitors
The clinical success of bortezomib validated the importance of the proteasome as a therapeutic target in MM. PR-171 is a novel epoxyketone-based irreversible proteasome inhibitor. Though approximately as potent as bortezomib, it is more selective for the chymotrypsin-like activity of the proteasome. Early in vitro data suggest that cytotoxicity follows even relatively short exposure of hematologic cell lines to PR-171, resulting in cell cycle arrest and/or apoptosis [65] . Preliminary data from the pharmaceutical company developing the compound report that a dose-and schedule-dependent antitumor response is seen in human tumor xenograft models, while clinical responses in the early stages of the clinical trials of this agent have also been reported [66] .
The other proteasome inhibitor under development is salinosporamide A (NPI-0052), a small molecule derived from fermentation of Salinospora, a new marine grampositive actinomycete. This agent has been shown to induce apoptosis in MM cells resistant to conventional and bortezomib therapies [67] . Synergistic activity was seen when NPI-0052, which has a toxicity profile distinct from bortezomib, was tested in combination with the latter agent. Biochemical and genetic studies show that NPI-0052, in contrast to bortezomib, relies more on FADD-caspase-8-mediated cell death signaling. Oral bioavailability and promising results from animal tumor models have led to ongoing clinical trials of this agent.
Heat shock protein 90 (Hsp90) inhibitors
Hsp90 inhibitors have been shown to activate multiple proapoptotic pathways in MM tumor cells and to sensitize them to other anticancer agents, including cytotoxic chemotherapy and the proteasome inhibitor bortezomib [68] . Given this preclinical evidence of potential synergy, 40 patients were enrolled in a multi-center phase I clinical trial of tanespimycin (17-AAG in the KOS-953 cremophor-based formulation) and bortezomib [69] . Encouragingly, responses were seen at all dose levels of KOS-953 where the bortezomib dose was greater than 1.0 mg/m 2 . For bortezomib-naive patients, the response rate was 71% (5/7 pts); for bortezomib-refractory patients (defined as progressive disease on bortezomib-containing regimen prior to study or no response to prior bortezomib), 33% (2/6 pts) responded; and for bortezomib-pretreated patients, responses were seen in 38% (5/13 pts). The toxicity profile of tanespimycin has been acceptable without significant cardiotoxicity, peripheral neuropathy or deep vein thrombosis. Durable disease stabilization and minor responses have also been seen when it has been used as a single agent in relapsed and refractory MM patients. These promising results from the combination phase I/II study and the lack of additive toxicity or pharmacokinetic interactions provide a platform for future phase III trials of this regimen, which are planned to start this year.
Histone deacetylase (HDAC) inhibitors
Normal cellular metabolism requires the clearance of cytotoxic misfolded proteins by both proteasomes and aggresomes. Among the roles of the microtubule-associated deacetylase HDAC6 is the transport of these misfolded aggregates to the aggresome. HDAC inhibitors therefore represent a promising class of agents. Either the intravenous (n=14) or the oral (n= 25) form of suberoylanilide hydroxamic acid (SAHA) was administered to patients with haematologic malignancies including MM in two phase I trials [70] . Side effects were fatigue, anorexia, diarrhea and dehydration. Though some myelosuppression was seen with the IV formulation, no neutropenic fever was seen. Tumor response was observed in 20% of patients. LBH589 is a novel hydroxamic acid-derived histone deacetylase inhibitor. Both MM cell lines and patient tumor samples were sensitive to nanomolar doses (IC 50 < 40 nmol/l) [71] . In addition, LBH589 potentiated the action of drugs, such as bortezomib, Dex, or melphalan. Clinical trials of both agents are in process.
Arsenic trioxide
Arsenic trioxide has been reported to have in vitro anti-MM activity in several studies [72] . In a phase II study of singleagent arsenic trioxide in relapsed and refractory MM, decrease in M-protein by >25% were reported in 8 (33%) of 24 patients [73] . The MAC combination regimen (melphalan, arsenic trioxide and ascorbic acid) was studied in 65 patients with advanced MM and was reported to be well tolerated, have an ORR of 48% with a median OS of 19 months [74] . The ABC protocol combines bortezomib with arsenic trioxide and ascorbic acid and was tested in 22 patients with heavily pretreated MM, leading to objective response in 6 (27%) patients and 12-month OS of 74% [75] .
Inhibitors of upstream kinase receptors (FGF-R3, IGF-1R), Akt (perifosine) and mTOR
Perifosine (Keryx Biopharmaceuticals, NY) is a synthetic novel alkylphospholipid (ALP), a new class of antitumor agents that target cell membranes. It has been shown to inhibit the phosphorylation of Akt in MM cells in a timeand dose-dependent manner and to induce apoptosis in both sensitive and resistant MM cell lines [76] . The cytotoxicity of ALPs in MM appears to operate via a novel lipid raftmediated mechanism involving the concentration of death receptors in membrane rafts with Fas/CD95 playing a major role in ALP-mediated apoptosis [77] . The recent finding that perifosine both has antitumor activity and also induces myeloid hyperplasia in a murine myeloma model provides further support for progressing with the clinical evaluation of this class of compounds [78] . Phase I/II studies of perifosine in combination with Dex and bortezomib are currently underway with promising results to date [79] .
Insulin-like growth factor 1 (IGF-1) is central to the pathophysiology of multiple myeloma. A small-molecule IGF1R tyrosine kinase inhibitor, NVP-ADW742 (Novartis Pharma AG, Switzerland) has shown significant cytotoxicity in vitro and in vivo in MM [80] . Targeting the IGF-1 receptor using picropodophyllin in the mouse 5T2MM model also showed strong antitumor activity and a significant OS advantage for treated mice [81] . The multiple roles of this signaling pathway were also reflected in significant inhibition of tumor-associated angiogenesis and osteolysis.
Fibroblast growth factor receptor 3 (FGFR3) expression is dysregulated ∼15% of MM patients because of t(4;14) chromosomal translocations. This subset of the disease has poor prognosis to conventional therapies, which has rendered FGFR3 an attractive target for development of new therapies. CHIR-258, a small-molecule inhibitor of multiple receptor tyrosine kinases inhibited tumor growth in an orthotopic murine MM model [82] . Other potential agents for this target include PRO-001, a highly specific anti-FGFR3-neutralizing antibody which induces apoptosis of primary t(4;14) MM samples [83] .
Inhibition of the transcriptional activity of nuclear factor (NF)-κB is one of the diverse pathways through which bortezomib and the immunomodulatory thalidomide derivatives affect MM cell survival. IκB kinase (IKK) phosphorylates IκB and promotes its proteasomal degradation thus allowing NF-κB to move to the nucleus and exert its transcriptional effects. Therefore IKK inhibitors contribute to inhibition of activation of NF-κB. MLN120B [84] and the anilinopyrimidine derivative AS602868 [85] are IKK inhibitors that are considered candidates for phase I/II trials.
Rapamycin and its analogs, CCI-779 (Wyeth Ayerst, PA, USA) and RAD001 (Everolimus, Novartis, NJ), inhibit the phosphoprotein, mTOR (mammalian target of rapamycin) and trigger anti-MM responses in preclinical models [86] . Preclinical data suggest that mTOR inhibitors may be combined with other anti-MM agents, e.g. Len [87] or the Hsp90 inhibitor 17-AAG [88] to achieve enhanced anti-MM effect. A phase I/II study of intravenous CCI-779 plus bortezomib in patients with relapsed MM is ongoing.
Inhibitors of angiogenesis: 2-Methoxyestradiol, VEGF-R inhibitors
2-Methoxyestradiol (2ME2) is an estrogen derivative that inhibits MM cell proliferation and induces their apoptosis. It also slows the growth of plasmacytomas xenografted in mice [89] . Clinical studies in MM suggest a favorable safety profile of 2ME2, which achieved sustained disease control in some patients that previously relapsed or were refractory to conventional treatments [90] .
Vascular endothelial growth factor (VEGF) has been implicated in tumor cell development, disease progression and drug resistance. Inhibition of the VEGF pathway may offer a novel method of improving patient outcome in MM [91] . The small-molecule VEGF receptor inhibitor pazopanib has been shown to inhibit VEGF-triggered signaling pathways in both tumor and endothelial cells, resulting in increased apoptosis, decreased angiogenesis, and prolonged survival in a mouse xenograft model of human MM [92] . Interestingly, however, there have been so far three reports of clinical trials of different VEGF-R inhibitors that have not achieved clinical responses in MM [93] [94] [95] .
Azaspirane Azaspirane (Atiprimod®) is an orally bioavailable cationic amphiphilic compound that significantly inhibited growth and induced caspase-mediated apoptosis in drug-sensitive and drug-resistant MM cell lines [96] . The cytotoxic effect also involves inhibition of cytokine secretion in the tumor microenvironment. In vivo antitumor activity has been demonstrated in a SCID mouse model and phase I trials are underway.
Defibrotide
In view of the critical role of the BM micronenvironment in interacting with MM cells and affecting the behavior of this disease, therapeutics that can target these interactions are now viewed to be of intriguing potential, not only because they may be able to enhance the anti-MM activity of existing conventional therapies, but also because they might allow for administration of these conventional agents in lower doses, in a manner that would not compromise clinical efficacy, but could conceivably reduce the incidence or severity of side effect. One such example of a microenvironment-targeting therapeutic is defibrotide (DF). DF is an orally bioavailable polydisperse polydeoxyribonucleotide that has a pleiotropic spectrum of protective effects on endothelial cells, without causing substantial systemic anticoagulant effects and without increase in risk of bleeding. DF has minimal, if any, in vitro inhibitory effect on MM cells in vitro. However, it does target the interactions of tumor cells with their microenvironment, including the adhesion of MM cells to BM stroma cells (BMSCs) and the resulting biological sequelae. These properties may account at least in part for the preclinical observation that DF can sensitizes MM to cytotoxic chemotherapy in preclinical in vivo models [97] . The fact that DF can protect patients against thrombosis, while potentially enhancing the sensitivity of their MM cells to other treatments provided the rationale for an ongoing phase I/II clinical trial to determine the efficacy and safety of a combination melphalan, prednisone, thalidomide, and DF (MPTD) as salvage treatment for MM patients with advanced disease [98] . Preliminary results on the first ∼30 patients of the trial indicate that MPTD shows promising evidence of antitumor MM in the relapsed and refractory setting, with a high rate (CR+PR: 53%) of durable responses, while the profile of side effects is manageable toxicities. The absence of significant non-hematologic toxicity with this regimen, including only a single case of DVT (with no other prophylaxis used) and the very low rates of neuropathy to date, are encouraging and suggest that further studies of DF-based treatments are warranted.
Conclusion
Bortezomib, thalidomide, and lenalidomide have changed the therapeutic management and favorably impacted the clinical outcome of MM. A key present goal of translational and clinical research is to optimally incorporate these new therapies in combination regimens with conventional chemotherapy and/or transplant-based therapeutic programs, as well as develop a framework whereby novel promising targeted therapies, such as those described in this review, could be partnered with key "backbone" combinations, such as the bortezomib plus lenalidomide (Rev-Vel) doublet. Optimization of sequencing of novel therapeutics and efforts to avoid overlapping toxicities will also be key future directions. 
